Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2025)
Historic Common Equity for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $332.0 million.
- Amylyx Pharmaceuticals' Common Equity rose 6921.05% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 6921.05%. This contributed to the annual value of $164.8 million for FY2024, which is 6198.6% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Common Equity stood at $332.0 million, which was up 6921.05% from $167.9 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Common Equity ranged from a high of $433.4 million in Q4 2023 and a low of -$151.2 million during Q4 2021
- Moreover, its 5-year median value for Common Equity was $251.1 million (2022), whereas its average is $250.4 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Common Equity soared by 32531.69% in 2022 and then plummeted by 6198.6% in 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' Common Equity (Quarter) stood at -$151.2 million in 2021, then skyrocketed by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then tumbled by 61.99% to $164.8 million in 2024, then skyrocketed by 101.5% to $332.0 million in 2025.
- Its last three reported values are $332.0 million in Q3 2025, $167.9 million for Q2 2025, and $201.4 million during Q1 2025.